Purpose Multiple myeloma (MM) is a hematologic malignancy characterized by a clonal expansion of plasma cells (PCs) in the bone marrow (BM). Since MM has so far remained incurable, further insights into its pathogenesis and the concomitant identification of new therapeutic targets are urgently needed. The tyrosine kinase receptor EphA3 is known to be involved in various cellular processes including cell viability, cell movement and cell-cell interactions.
Introduction
Multiple myeloma (MM) is an incurable plasma cell (PC) malignancy accounting for approximately 13% of all hematologic cancers [1] . In the past, several novel agents have been introduced into clinical practice with significant benefits in terms of patient response rates [2] . However, after an initial response, most patients relapse or progress with treatmentrefractory disease [3] . Unlike small molecule inhibitors, monoclonal antibodies (mAbs) directed against antigens that are highly expressed on the surface of malignant cells carry the benefits to specifically target tumor cells [4] . MAbs, such as elotuzumab and daratumumab, have been shown to result in objective clinical responses and to contribute to the immunological control of disease [4, 5] . Therefore, the identification and characterization of novel surface antigens on MM PCs [6] and the assessment of the therapeutic efficacies of its corresponding mAbs are warranted.
The Eph family of tyrosine kinase receptors and their ligands, the ephrins, are components of signal transduction pathways that play crucial roles in cellular protrusions, adhesion and migration through cytoskeleton remodelling [7, 8] . Although these processes are important in cancer progression, the relationship between Eph receptors and tumorigenesis remains largely undefined [9] . Recently, the Eph receptor A3 (EphA3) has emerged as a potential therapeutic target [10] [11] [12] since it was found to be overexpressed in various malignancies, including leukemias, gastric and hepatocellular carcinomas and glioblastomas [11] [12] [13] [14] [15] [16] . EphA3 was also found to be overexpressed in the microenvironment of different human cancers and its targeting was found to inhibit tumor growth by disrupting the supportive stroma and vasculature [17] . Recently, a novel EphA3 targeting mAb (KB004) was evaluated in a phase I clinical trial in subjects with EphA3 expressing myeloid malignancies refractory to conventional treatments (NCT01211691). It was reported that KB004 was well tolerated and clinically active in these patients [18] . As yet, no data are available on the efficacy of EphA3mAb in MM.
Here, we set out to assess the role of EphA3 and its targeting by EphA3mAb in MM. We evaluated the expression of EphA3 in MM primary BMPCs and in MM-derived cell lines compared to healthy controls (HCs). Using siRNAmediated Bloss of function^and EphA3mAb treatment approaches we studied in vitro effects on both cell viability and movement. In addition, we studied in vivo effects of EphA3mAb treatment in two MM mouse xenograft models.
Materials and methods

Cell lines and primary cells
Detailed information on the MM-derived cell lines, growth conditions and patient characteristics are provided in the Supplementary Methods. MM cells and primary bone marrow (BM) stromal cells (BMSCs) were obtained from BM mononuclear cells as indicated in the Supplementary Methods. The study was approved by the Ethics Committee of IRCCS-CROB (Prot. 3725; 07/02/2008) and all patients provided informed consent according to the Declaration of Helsinki.
Quantitative real-time PCR and expression data analysis
RNA from cell lines was extracted using a RNeasy mini kit (Qiagen, Hilden, Germany). First strand cDNA was synthesized using random hexamers and a Transcriptor High Fidelity cDNA Synthesis Kit (Roche Applied Science, Mannheim, Germany). For the expression analyses of EphA3, vimentin (VIM), C-X-C chemokine receptor type 4 (CXCR4), alphacatulin (CTNNAL1) and tissue inhibitor of metalloproteinases (TIMP1) by quantitative real-time PCR (qRT-PCR) a TaqMan® Gene Assays kit (Applied Biosystems) and a SYBR Green I Master kit (Roche Applied Science) were used, respectively, following the manufacturer's instructions. The cycling conditions and primers used are listed in the Supplementary Methods. EphA3 expression analyses using published gene expression datasets are also provided in the Supplementary Methods.
Western blotting
Cells were lysed and proteins were blotted as previously reported [19] . All further details are provided in the Supplementary Methods.
Flow cytometry
Immunofluorescence flow cytometric analyses were performed using a FACSCalibur™ (BD). The antibodies and conditions used are provided in the Supplementary Methods.
siRNA-mediated EphA3 silencing
siRNA-mediated EphA3 silencing (shEphA3) in SKMM1 and U266 cells and its respective scramble controls (shCTR) were performed using a lentiviral system (Santa Cruz Biotechnology, Santa Cruz, CA). The cell lines were infected with 1 × 10 5 recombinant lentivirus-transducing units in the presence of 6 μg/ml polybrene according to the manufacturer's instructions (Santa Cruz Biotechnology).
Viability and proliferation assays
The viability and proliferation rates of shEphA3 and shCTR transduced (SKMM1 and U266) and nontransduced (SKMM1, JJN3 and MM.1S) MM-derived cells treated or not with EphA3mAb (7.5-18 μg/ml, kindly provided by Prof. Lackmann) were assessed by Trypan blue exclusion and 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt (MTS, Promega, Madison, WI) assays, respectively. Details are provided in the Supplementary Methods.
Cell adhesion to fibronectin and BMSCs
48-Well microtiter plates were coated with fibronectin (FN; 10 μg/ml in PBS) after which 4 × 10 5 MM-derived cells in 100 μl were plated per well and incubated at 37°C for 45 min in the presence or absence of EphA3mAb (7.5-18 μg/ml). BMSCs were cultured overnight to confluence in 96-well plates (7.5 × 10 3 cells/well). Subsequently, MM PKH67 positive PCs were added to the BMSC-coated wells (1 × 10 5 cells/ well) for 2 h at 37°C in the presence or absence of EphA3mAb (7.5-18 μg/ml). Details are provided in the Supplementary Methods.
Transwell invasion assay
Matrigel coated invasion chambers were used to investigate the effect of EphA3 silencing and EphA3mAb treatment on the in vitro invasion of SKMM1 and U266 cells. Details are provided in the Supplementary Methods.
Gene expression profiling
Sample hybridization and scanning of Illumina HumanHT12 v4.0 Expression BeadChip arrays (Illumina Inc., San Diego, CA, USA) on a HiScanSQ system (Illumina Inc.) were performed as previously reported [20] and are described in the Supplementary Methods.
Mouse xenograft models
Four weeks old NOD/SCID mice (Harlan Laboratories, Udine, Italy) were housed under pathogen-free conditions. Three groups (A-C) of five animals were injected subcutaneously with 10 × 10 6 MM-derived JJN3 or MM1S cells. Starting from three days after MM cell inoculation, group A received subcutaneously 75 μg EphA3mAb (chIIIA4) three times a week, whereas group B received control isotype Abs and group C received PBS. Fourteen days after MM cell inoculation, the mice were sacrificed after which autopsies were carried out. Tumor masses were removed and measured using a caliper. The experiments were repeated twice using the same schedules and numbers of mice. Differences in tumor volume were evaluated by Mann-Whitney test with a 99% confidence interval (CI). All statistical tests were 2-tailed. A p value < 0.05 was considered to be statistically significant.
Xenograft evaluations
Tissue samples from MM xenografts obtained by inoculating JJN3 or MM1S cells were treated as indicated in the Supplementary Methods. Cell counts were performed at 400× in 0.18 mm 2 fields. At least 3 samples (1 sample/ tumor growth area) and 8-10 randomly chosen fields/sample were evaluated. Variables were reported as mean ± standard deviation (SD). Differences in cell count, among the three groups analysed, were assessed by One-way ANOVA analysis of variance with a p value < 0.001 as significance cut-off. The difference between each pair of means was evaluated using the Tukey pairwise multiple comparisons test.
Statistical analyses
GraphPad Prism 6 Software (La Jolla, CA) was used for statistical analyses. Data are presented as means ± SD. Statistical significance was determined by t-test or One-way ANOVA analysis.
Results
EphA3 is overexpressed in primary MM cells and in MM-derived cell lines
Using qRT-PCR, we found that the EphA3 mRNA expression level progressively increased in BMPCs from healthy controls (HCs) to those from MM subjects (Fig. 1a ). An additional analysis of EphA3 levels in published gene expression datasets confirmed our results in a large number of HCs and MM subjects ( Supplementary Fig. 1 ). We also found that the EphA3 protein was overexpressed in MM BMPCs compared to HCs using flow cytometry (Fig. 1b) . In addition, we observed higher EphA3 mRNA expression levels in 11 MMderived cell lines compared to HCs, but these levels were lower than those observed in primary MM cells (Fig. 1a) . The EphA3 protein was also overexpressed in the MMderived cell lines compared to HCs as determined by flow cytometry (Fig. 1b) .
EphA3 silencing in MM-derived cell lines
To investigate the functional role of EphA3 in MM, the EphA3 expression was silenced in the MM-derived cell lines SKMM1 and U266 using lentiviral transduction (shEphA3 SKMM1/U266 and shCTR SKMM1/U266, respectively). The first cell line (SKMM1) expresses high EphA3levels, while the second cell line (U266) expresses relatively lower EphA3 levels. A major reduction in EphA3 mRNA and protein levels (−80% and −70%, respectively) was observed in shEphA3 SKMM1 cells compared to shCTR SKMM1 cells (Fig. 2a, b) . Similar results were obtained in shEphA3 U266 cells compared to shCTR U266 cells, i.e., both the EphA3 mRNA and protein levels were down-regulated by −76% and −45%, respectively ( Supplementary Fig. 2a, b ).
EphA3 silencing has no effect on the proliferation and viability of MM cells
We assessed the effect of EphA3 silencing on the proliferation and viability of the respective MM-derived cell lines. We found that EphA3 silencing did not affect the proliferation and viability over a time course of 24 to 96 h in shEphA3 SKMM1 cells (Fig. 3a, b) . A similar result was obtained with shEphA3 U266 cells ( Supplementary Fig. 2c, d ).
EphA3 silencing inhibits the adhesion and invasion of MM cells
Using cell adhesion assays, we found that EphA3-silenced cells exhibited a significant reduction in adhesion to FN (−45%, p = 0.0007) and to MM BMSCs (−35%, p = 0.0008) compared to shCTR cells (Fig. 3c, d ). Using Matrigel® invasion assays, we also observed a significant reduction in invasion (−60%, p = 0.001) of EphA3-silenced cells compared to control shCTR transduced cells (Fig. 3e) . Compared to shCTR U266 cells, hEphA3 U266 cells exhibited a reduction in adhesion to FN (−35%, p < 0.001) and to BMSCs (−30%, p < 0.001), as well as in invasion (−33%, p = 0.001; Supplementary Fig. 2e-g ). 
EphA3 silencing results in altered expression of genes involved in cell movement
After gene expression profiling (GEP) we found that 896 mRNAs were differentially expressed (462 up-and 470 downregulated) in EphA3-silenced cells compared to shCTR control cells. Subsequent DAVID and Ingenuity functional annotation analyses revealed a significant enrichment of genes involved in cell movement including adhesion, migration and invasion. In Fig. 4a some of these movement-related genes, such as VIM, CXCR4, CTNNAL1 and TIMP1, are indicated. Using qRT-PCR analysis, we confirmed the downregulation of VIM, CXCR4 and CTNNAL1 and the upregulation of TIMP1 in the EphA3-silenced versus shCTR control cells (Fig. 4b ). In addition, we confirmed VIM protein downregulation and CXCR4 protein up-regulation in EphA3-silenced cells compared to shCTR control cells using Western blotting and flow cytometric assays, respectively (Fig. 4c, d ).
3.6 EphA3mAb treatment has no effect on the proliferation and viability of MM cells Next, we investigated the effect of EphA3mAb treatment on the proliferation and viability of the MM-derived cell lines SKMM1, JJN3 and MM1S. We found that treatment with increasing amounts of the anti-EphA3 mAb for 24 or 48 h did not affect the proliferation nor the viability of all cell lines tested (Fig. 5a, b and Supplementary Fig. 3 ).
EphA3mAb treatment reduces cell adhesion and invasion of MM cells
We also investigated the effect of EphA3mAb treatment on the adhesion to FN and BMSCs of SKMM1 cells. By doing so, we found that EphA3mAb treatment resulted in a reduced adhesion to FN (−20%, and −30%; p < 0.01) and to BMSCs (−38% and 34%; p < 0.01) compared to untreated cells in a dose-dependent manner (Fig. 5c, d ). Using an invasion assay, we observed a significantly reduced invasion (−20% and −23%; p < 0.05) of treated versus untreated cells (Fig. 5e ).
EphA3mAb treatment inhibits MM xenograft growth and angiogenesis
Next, we set out to study the effect of EphA3mAb treatment on JJN3 and MM1S MM-derived tumor cell growth in NOD/ SCID mice. The first cell line (JJN3) expresses high EphA3 levels, whereas the second cell line (MM1S) expresses relatively low EphA3 levels. The MM cells were embedded in matrigel and inoculated subcutaneously in mice. Every two days for 15 days, anti-EphA3, control Ab or vehicle were administered subcutaneously to the different mouse groups. At the end of the treatment the tumor volumes were measured and, subsequently, the tumors were subjected to immunohistochemistry (morphological aspects), apoptosis index, proliferation rate and angiogenesis measurements. We found that EphA3mAb treatment significantly inhibited JJN3 MMderived tumor growth compared to control Ab or vehicle treatment (Fig. 6a) . The tumors that developed in untreated mice or mice treated with the control Ab were formed by round to oval cells showing morphological aspects of mononuclear and, occasionally, multinucleated cells with prominent nucleoli and frequent mitoses (Fig. 6b: a, e) . In contrast, we found that tumors derived from EphA3mAb treated mice showed foci of ischemic-hemorrhagic necrosis (Fig. 6b, i: N) . In addition, we found that the proliferative activity, as measured by Ki67 antigen expression, was not different in tumors from EphA3mAb treated mice compared to controls (Fig. 6b: c, g,  k) . We did find, however, that the apoptotic index as assesed by TUNEL assay was significantly increased in tumors derived from EphA3mAb treated mice compared to those from control mice (p < 0.001, Fig. 6b : d, h, l). Immunostaining using anti-vessel antigen (CD31) Abs revealed a reduction in vessel number in tumors derived from EphA3mAb treated mice compared to those from controls ( Fig. 6b: b, f, j) . We also found that EphA3mAb treated tumors showed monocyte and macrophage infiltrations, particularly at the tumor edges, in Representative images of the adhesion and invasion assays were acquired using fluorescence and bright light microscopy, respectively. 10× magnification was used for all images.
Data of adhesion to FN and of invasion in the bar plots are presented as percentages of the respective controls (mean ± SD of triplicates from 3 independent experiments). For the adhesion to BMSCs data are presented as percentages of the respective controls and shown as means ± SD of 3 experiments on 3 BMSCs by analysing five random fields for each experiment close proximity with apoptotic tumor cells (F4/80 staining in insert of Fig. 6b-l) . In the second MM1S MM-derived xenograft model, characterized by a lower EphA3 expression, all the above data were confirmed. In particular, we found that EphA3mAb treatment significantly inhibited tumor growth (p < 0.05; Fig. 7a ). Also. immunohistochemistry revealed a reduction in angiogenesis ( Fig. 7b : b, f, j), an increased apoptotic index (Fig. 7b : d, h, l) and monocyte and macrophage infiltrations (insert of Fig. 7b-l) .
Discussion
The pathobiological complexity of MM and its increased prevalence in the elderly have proved problematic for the development of safe and effective therapies for this malignancy [21] . New high-throughput technologies have allowed a better understanding of the molecular basis of MM and, as a result, have opened up possibilities fror precision medicine [22] . Recently, several MM cell surface-associated targets, including CD38, CD74 and CD138, have emerged as potential new immune targets for the treatment of MM [4, 23, 24] . Here, we show for the first time that the EphA3 receptor is expressed in primary MM PCs and that its presence is elevated in these cells compared to PCs from HCs. It has been found that EphA3 plays a critical role in different hematologic and solid tumors [12, 25, 26] and it has been recognised as an anticancer target that is highly expressed in leukemic cells [12, 27, 28] . It has been reported that EphA3 upregulation in hematologic malignancies may be brought about by signaling molecules or growth factors, such as the insulin-like growth factor, or by hypomethylation of the EphA3 gene promoter, gene copy number variations or somatic mutations [14, [29] [30] [31] . In addition, it has been reported that its expression may increase after s-thalidomide treatment in a MM-derived cell line [32] .
One of the hallmarks of MM is the spreading of malignant PCs throughout the BM [33] . This process is controlled by different molecules, such as surface receptors, integrins and chemo-attractants that affect the motility and shape of PCs [34, 35] . We found that si-RNA-mediated EphA3 silencing affects the behaviour of MM PCs. According to previous data indicating that EphA3 silencing in pre-B acute lymphoblastic leukemia (ALL) cells may inhibit their adhesion to FN [36] , we found that EphA3 is necessary for MM PC adhesion to FN and BMSCs. It is thought that adhesion-induced drug resistance is associated with an increased adhesion to FN and with an upregulation of integrin 5 [37] . As such, MM PCs characterized by high EphA3 expression are anticipated to exhibit a drug-resistant phenotype. Recently, it was shown that EphA3 is involved in regulating multidrug resistance in small-cell lung cancer (SCLC) cells and, as such, may serve as a new therapeutic target in these patients [38] .
Cell-cell interactions of MM cells with stromal cells have been found to lead to an increased release of interleukin 6 by In vitro activity of anti EphA3-specific antibody. SKMM1 cells were treated with anti-EphA3 Ab (7.5μg/ml and 18μg/ml) or not for 24 and 48 h and analysed for proliferation (a) viability (b), adhesion to fibronectin, FN (c), adhesion to MM bone marrow stromal cells, BMSCs (d) and Matrigel invasion (e). Representative images of adhesion to BMSCs and invasion assays were acquired with using fluorescence and bright light microscopy, respectively. 10× magnification was used for all images. Data are presented as percentages of the respective controls (mean ± SD of triplicates from 3 independent experiments) for viability, proliferation, adhesion to FN and invasion. For the adhesion to BMSCs the data are presented as percentages of the respective controls and are shown as means ± SD of 3 experiments on 3 BMSCs by analysing five random fields for each experiment. * and ** indicate p < 0.05 and p < 0.01, respectively Results in the bar graphs are presented as mean ± SD of CD31-positive micro-vessels per field, or Ki-67 or TUNEL-positive cells/number of total cells for the proliferation and apoptosis indexes, respectively (right panels). *** indicates p < 0.001 stromal cells, which in turn promotes the proliferation of MM cells and protects them from apoptosis induced by anticancer agents [39] . Despite the fact that specific receptors involved in de novo drug resistance elicited by MM-BMSC interactions have not been fully identified [39] , our data suggest that EphA3 may be a new player in interactions between MM PCs and BMSCs.
We also found that EphA3 expression downregulation inhibited the invasive capacity of MM-derived cells and that this downregulation may, therefore, have a beneficial effect on MM. In agreement with our data, it has been shown by others that EphA3 can affect the growth and migration/invasion of cancer cells in vitro and can modify tumor growth, invasiveness, angiogenesis and metastasis in vivo [14, 26] . Interestingly, similar shRNA-mediated effects were observed in MM PCs with different EphA3 expression levels such as SKMM1 (15,000 EphA3 copies) and U266 (1300 EphA3 copies) cells. We speculate that, based on the great variability in EphA3 expression levels observed among primary patient samples and MM-derived cell lines, even a low EphA3 expression may be important in the pathophysiology of MM.
Though we did not investigate EphA3 signaling pathways involved in both adhesion and invasion reduction, we analysed gene expression profiles (GEPs) in EphA3-silenced cells. These analyses revealed that EphA3 expression downregulation is accompanied by changes in genes involved in migration, invasion and trafficking processes, such as TIMP1, VIM, CTNNAL1 and CXCR4. In particular, we found an upregulation of TIMP1 and a downregulation of the other above-mentioned genes in EphA3-silenced cells. In line with our data, others found by GEP of purified CD138 + cells of 320 newly diagnosed MM patients a down regulation of TIMP1 [40] . In a previous study, we observed a role of VIM in the regulation of MM endothelial cell adhesion and migration and that primary MM PCs overexpress VIM [41] . Cytoplasmic CTNNAL1 binds to β-catenin and may have, therefore, potential effects on apoptosis and cytoskeletal reorganization. Similar to our previous findings, its knockdown inhibited cell migration and invasion in small lung cancer [42] [43] [44] .
Interestingly, we found that CXCR4 is down-modulated in EphA3-silenced PCs. Moller et al. [45] found that the CXCR4 chemokine receptor is expressed on MM cells that migrate in response to its ligand, SDF-1. The CXCR4 inhibitor AMD3100 drives disruption of the interaction of BM cells with MM PCs by mobilization of MM cells into the circulation, thereby increasing the efficacy of cytotoxic drugs in MM therapy [46] . This concept may lead to new approaches in the treatment of MM, modulating the ability of MM cells to reside in their supportive microenvironment. Our data seem to support this notion, since EphA3 silencing results in a reduction of CXCR4 expression which could lead to the mobilization of PCs, thus enabling a sensitizing effect to treatment. We, therefore, suggest that downregulation of EphA3 leads to the modulation of molecules that, on one hand block the invasive capacity of PCs and on the other hand drive their detachment from the tumor-supportive microenvironment, possibly increasing their sensitivity to drug treatment.
Recently, the first positive results from a phase 1 study on EphA3mAb KB004 treatment in patients with advanced hematologic myeloid malignancies have been reported [18] . Here, we used the chimeric form of KB004, IIIA4mAb [10, 47, 48] , which recognizes a conformational epitope in the highly conserved N-terminal domain of EphA3, a common region to human and mouse [49] . In agreement with Charmasaz et al. [12] , who showed effects of the antiEphA3m IIIA4mAb on leukemic cell movement, we observed a decrease in adhesion to FN and to MM-BMSCs and an impaired capacity to invade in vitro by treating MM PCs with EphA3mAb (chIIIA4mAb). The mechanism through which EphA3mAb blocks MM PC adhesion and motility remains to be investigated, but we speculate that EphA3mAb may modulate EphA3 signaling, thereby reshaping its conformation and interfering with signal transduction.
Our treatment of MM xenograft mice with IIIA4mAb resulted in an effective reduction of tumor sizes in conjunction with a significantly increased apoptosis. Whereas cell proliferation was not found to be affected, the increased apoptotic rate may account for the observed reductions in tumor sizes. In the in vivo experiments the EphA3 mAb was administered every two days, which may explain the difference in the anti-apoptotic effects observed in vitro. In fact, the EphA3mAb failed to inhibit the growth of cultured MMderived cells after a single mAb treatment from 24 h to 48 h. Importantly, we found that tumor reduction also occurred in a second MM xenograft mouse model with low EphA3 expression levels. This observation supports the idea that the antibody works well, also when low amounts of EphA3 are present. Recently, Chamasaz et al. [12] reported anti-tumor effects of IIIA4 mAb in EphA3 expressing leukemic xenografts. Excitingly, we observed after EphA3mAb treatment macrophage infiltration in the tumors, which could be responsible for an antibody-dependent cellular phagocytosis. This notion might indicate that EphA3mAb reduces in vivo tumor growth through the induction of apoptosis and immune effector-cell mediated killing rather than through inhibiting tumor cell proliferation per se. This option is in agreement with Chamasaz et al. [12] who showed Fc-mediated effects in leukemic xenografts treated with IIIA4 mAb. Moreover, Vail et al. [17] found that EphA3mAb IIIA4 binds to peripheral blood monocytes from BALB/c nu/nu mice through the FcgII/III receptor, whereas combined treatment of EphA3-positive mesenchymal stromal cells with chIIIA4 and effector cells caused a rapid cell contraction. Furthermore, Tomasevic et al. [49] found that humanized EphA3mAb induced a potent dose dependent ADCC mediated by peripheral blood monuclear cells against chronic myeloid leukemia BM cells. We cannot, however, exclude alternative in vivo mechanisms of action, such as complement-dependent cytotoxicity. In line with this, it has been reported that chimeric and humanized anti-CD38, anti-B cell activating factor or anti-CD74 Abs are able to kill MM cells by activating all of these mechanisms [4, 50] .
We also noted a high reduction in tumor vessels after EphA3mAb treatment in MM-derived xenograft mouse models. One possible explanation for this is that EphA3mAb indirectly reduces tumor angiogenesis by killing tumor cells. In leukemic mouse models, the effect of IIIA4 treatment was found to be specifically directed against tumor cells, with no apparently detectable activity on stromal cells. Furthermore, EphA3 expression has been reported in a broad range of solid human tumors and in mouse tumor xenografts, in particular in BM mesenchymal/stromal cells, and that EphA3mAb can inhibit tumor growth by disrupting the integrity and function of newly formed tumor stroma and microvasculature [17] . Previously, we found that EphA3 is overexpressed in primary MM endothelial cells (MMECs) compared to HCs and that EphA3mAb treatment showed in vitro anti-angiogenic effects in these latter cells [51] . Consequently, we cannot exclude other in vivo mechanisms of EphA3mAb action, such as the direct killing of MMECs. Additional work will be needed to resolve this matter.
Our current findings support the option to investigate the efficacy of anti-EphA3mAb treatment in clinical studies. In particular, the observed presence of EphA3 on MM plasma cells and MMECs and the demonstration of anti-EphA3 actions on both cell populations [51] suggest the design of a new potential immunotherapy against tumor growth and pathological angiogenesis in MM. In addition, it has been reported that EphA3 expression may increase after immunomodulatory drug (IMiD) treatment, such as thalidomide or lenalidomide [32, 51] . This notion forms a rationale for a combination therapy with IMiDs and an EphA3 inhibitor, such as EphA3mAb.
In conclusion, our findings indicate that EphA3 may serve as a novel regulator of MM PC trafficking through adhesion and invasion modulation. In addition we found that EphA3 targeting using a mAb induces MM tumor reduction in in vivo xenograft models. These data, together with the favourable clinical properties of humanized EphA3mAb reported in a phase I trial, support EphA3 and its targeting as a new potential therapeutic option for MM.
